Is 9-OH (9-hydroxycorynantheidine) Legal in Connecticut? (2026)

Instrument

CT Schedule I controlled substances — subsection (c) (kratom + 7-OH)

Source

https://eregulations.ct.gov/eRegsPortal/Browse/RCSA/Title_21aSubtitle_21a-243Section_21a-243-7/

Retrieved

2026-07-06

Fingerprint

b602a77314ad240e

(c) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (44) 7-hydroxymitragynine; (45) Bromazolam; (46) Flubromazolam; (47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts; (48) Nitazenes, including, but not limited to, isotonitazene; (49) Tianeptine; and (50) Phenibut. (Effective July 23, 1987; Amended ... Amended February 10, 2023; Amended April 2, 2026) [Full (a)-(g) section available at official URL; subsection (c) is the operative kratom-scheduling instrument, items (44) and (47) captured verbatim.]

Instrument

Regulations. Schedules of controlled substances.

Source

https://www.cga.ct.gov/2026/sup/chap_420b.htm

Retrieved

2026-10-29

Fingerprint

f6e3e29604926659

Sec. 21a-243. (Formerly Sec. 19-451). Regulations. Schedules of controlled substances.
 (a) The Commissioner of Consumer Protection shall adopt regulations for the efficient enforcement and operation of sections 21a-244 to 21a-282, inclusive.

(b) The Commissioner of Consumer Protection may, so far as may be consistent with sections 21a-244 to 21a-282, inclusive, adopt the regulations existing under the federal Controlled Substances Act and pertinent regulations existing under the federal food and drug laws and conform regulations adopted hereunder with those existing under the federal Controlled Substances Act and federal food and drug laws.

(c) The Commissioner of Consumer Protection, acting upon the advice of the Commission of Pharmacy, may by regulation designate, after investigation, as a controlled substance, a substance or chemical composition containing any quantity of a substance which has been found to have a stimulant, depressant or hallucinogenic effect upon the higher functions of the central nervous system and having a tendency to promote abuse or physiological or psychological dependence or both. Such substances are classifiable as amphetamine-type, barbiturate-type, cannabis-type, cocaine-type, hallucinogenic, morphine-type and other stimulant and depressant substances, and specifically exclude alcohol, caffeine and nicotine. Substances which are designated as controlled substances shall be classified in schedules I to V by regulations adopted pursuant to subsection (a) of this section.

(d) The Commissioner of Consumer Protection may by regulation change the schedule in which a substance classified as a controlled substance in schedules I to V of the controlled substance scheduling regulations is placed. On or before December 15, 1986, and annually thereafter, the commissioner shall submit a list of all such schedule changes to the chairmen and ranking members of the joint standing committee of the General Assembly having cognizance of matters relating to public health.

(e) The Commissioner of Consumer Protection shall classify marijuana as a controlled substance in schedule II under the Connecticut controlled substance scheduling regulations, except that for any marijuana product that has been approved by the federal Food and Drug Administration or successor agency to have a medical use and that is reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency, the commissioner shall adopt the schedule designated by the Drug Enforcement Administration or successor agency. In the event that marijuana is reclassified as a controlled substance in schedule III, IV or V of the federal Controlled Substances Act, or is unscheduled by the federal Drug Enforcement Administration or successor agency, the commissioner shall adopt the schedule designated by the federal Drug Enforcement Administration or successor agency.

(f) A new or amended regulation under this chapter shall be adopted in accordance with the provisions of chapter 54.

(g) In the event of any inconsistency between the contents of schedules I, II, III, IV and V of the controlled substance scheduling regulations and schedules I, II, III, IV and V of the federal Controlled Substances Act, as amended, the provisions of the federal act shall prevail, except (1) when the provisions of the Connecticut controlled substance scheduling regulations place a controlled substance in a schedule with a higher numerical designation, schedule I being the highest designation, or (2) as provided in subsection (e) of this section.

(h) When a drug that is not a controlled substance in schedule I, II, III, IV or V, as designated in the Connecticut controlled substance scheduling regulations, is designated to be a controlled substance under the federal Controlled Substances Act, such drug shall be considered to be controlled at the state level in the same numerical schedule from the effective date of the federal classification. Nothing in this section shall prevent the Commissioner of Consumer Protection from designating a controlled substance differently in the Connecticut controlled substance scheduling regulations than such controlled substance is designated in the federal Controlled Substances Act, as amended from time to time.

(i) (1) The Commissioner of Consumer Protection shall, by regulation adopted pursuant to this section, designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances and classify each such substance in the appropriate schedule:

(A) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);

(B) 1-butyl-3-(1-naphthoyl)indole (JWH-073);

(C) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

(D) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);

(E) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47,497 C8 homologue);

(F) Salvia divinorum; and

(G) Salvinorum A.

(2) Notwithstanding the provisions of subsection (c) of this section, the commissioner shall, in accordance with the provisions of chapter 54, amend the regulations adopted pursuant to subdivision (1) of this subsection to designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances and classify each such substance in the appropriate schedule:

(A) 7-hydroxymitragynine;

(B) Bromazolam;

(C) Flubromazolam;

(D) Mitragyna speciosa (kratom), including its leaves, stem and any extracts;

(E) Nitazenes, including, but not limited to, isotonitazene;

(F) Tianeptine; and

(G) Phenibut.

(j) Notwithstanding the provisions of subsection (c) of this section, the Commissioner of Consumer Protection shall designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances in schedule I of the controlled substances scheduling regulations:

(1) Mephedrone (4-methylmethcathinone);

(2) Synthetic cannabinoids; and

(3) MDPV (3,4-methyenedioxypyrovalerone).

(1967, P.A. 555, S. 7; 737; 1969, P.A. 753, S. 4; 1972, P.A. 278, S. 2; P.A. 73-681, S. 3, 29; P.A. 86-96, S. 6, 7; P.A. 87-129, S. 3; P.A. 99-175, S. 49; June 30 Sp. Sess. P.A. 03-6, S. 146(c); P.A. 04-189, S. 1; P.A. 11-73, S. 1; 11-210, S. 3; P.A. 12-55, S. 18; P.A. 19-177, S. 30, 31; P.A. 24-115, S. 2; P.A. 25-101, S. 4.)

Instrument

Regulations. Schedules of controlled substances; Controlled substances in schedule I, subsection (c)

Source

https://eregulations.ct.gov/eRegsPortal/Search/getDocument?guid=003D4E9D-0000-C41E-9994-EE4C018247EA

Retrieved

2026-11-08

Fingerprint

e16a25de95d36163

Sec. 21a-243.

(a) The Commissioner of Consumer Protection shall adopt regulations for the efficient enforcement and operation of sections 21a-244 to 21a-282, inclusive.

(b) The Commissioner of Consumer Protection may, so far as may be consistent with sections 21a-244 to 21a-282, inclusive, adopt the regulations existing under the federal Controlled Substances Act and pertinent regulations existing under the federal food and drug laws and conform regulations adopted hereunder with those existing under the federal Controlled Substances Act and federal food and drug laws.

(c) The Commissioner of Consumer Protection, acting upon the advice of the Commission of Pharmacy, may by regulation designate, after investigation, as a controlled substance, a substance or chemical composition containing any quantity of a substance which has been found to have a stimulant, depressant or hallucinogenic effect upon the higher functions of the central nervous system and having a tendency to promote abuse or physiological or psychological dependence or both. Such substances are classifiable as amphetamine-type, barbiturate-type, cannabis-type, cocaine-type, hallucinogenic, morphine-type and other stimulant and depressant substances, and specifically exclude alcohol, caffeine and nicotine. Substances which are designated as controlled substances shall be classified in schedules I to V by regulations adopted pursuant to subsection (a) of this section.

(d) The Commissioner of Consumer Protection may by regulation change the schedule in which a substance classified as a controlled substance in schedules I to V of the controlled substance scheduling regulations is placed. On or before December 15, 1986, and annually thereafter, the commissioner shall submit a list of all such schedule changes to the chairmen and ranking members of the joint standing committee of the General Assembly having cognizance of matters relating to public health.

(e) The Commissioner of Consumer Protection shall classify marijuana as a controlled substance in schedule II under the Connecticut controlled substance scheduling regulations, except that for any marijuana product that has been approved by the federal Food and Drug Administration or successor agency to have a medical use and that is reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency, the commissioner shall adopt the schedule designated by the Drug Enforcement Administration or successor agency. In the event that marijuana is reclassified as a controlled substance in schedule III, IV or V of the federal Controlled Substances Act, or is unscheduled by the federal Drug Enforcement Administration or successor agency, the commissioner shall adopt the schedule designated by the federal Drug Enforcement Administration or successor agency.

(f) A new or amended regulation under this chapter shall be adopted in accordance with the provisions of chapter 54.

(g) In the event of any inconsistency between the contents of schedules I, II, III, IV and V of the controlled substance scheduling regulations and schedules I, II, III, IV and V of the federal Controlled Substances Act, as amended, the provisions of the federal act shall prevail, except (1) when the provisions of the Connecticut controlled substance scheduling regulations place a controlled substance in a schedule with a higher numerical designation, schedule I being the highest designation, or (2) as provided in subsection (e) of this section.

(h) When a drug that is not a controlled substance in schedule I, II, III, IV or V, as designated in the Connecticut controlled substance scheduling regulations, is designated to be a controlled substance under the federal Controlled Substances Act, such drug shall be considered to be controlled at the state level in the same numerical schedule from the effective date of the federal classification. Nothing in this section shall prevent the Commissioner of Consumer Protection from designating a controlled substance differently in the Connecticut controlled substance scheduling regulations than such controlled substance is designated in the federal Controlled Substances Act, as amended from time to time.

(i) (1) The Commissioner of Consumer Protection shall, by regulation adopted pursuant to this section, designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances and classify each such substance in the appropriate schedule:

(A) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);

(B) 1-butyl-3-(1-naphthoyl)indole (JWH-073);

(C) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

(D) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);

(E) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47,497 C8 homologue);

(F) Salvia divinorum; and

(G) Salvinorum A.

(2) Notwithstanding the provisions of subsection (c) of this section, the commissioner shall, in accordance with the provisions of chapter 54, amend the regulations adopted pursuant to subdivision (1) of this subsection to designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances and classify each such substance in the appropriate schedule:

(A) 7-hydroxymitragynine;

(B) Bromazolam;

(C) Flubromazolam;

(D) Mitragyna speciosa (kratom), including its leaves, stem and any extracts;

(E) Nitazenes, including, but not limited to, isotonitazene;

(F) Tianeptine; and

(G) Phenibut.

(j) Notwithstanding the provisions of subsection (c) of this section, the Commissioner of Consumer Protection shall designate the following substances, by whatever official, common, usual, chemical or trade name designation, as controlled substances in schedule I of the controlled substances scheduling regulations:

(1) Mephedrone (4-methylmethcathinone);

(2) Synthetic cannabinoids; and

(3) MDPV (3,4-methyenedioxypyrovalerone).

Sec. 21a-243-7. Controlled substances in schedule I
The controlled substances listed in this regulation are included by whatever official, common,
usual, chemical, or trade name designation in schedule I:

(c) Unless specifically excepted or unless listed in another schedule in the Connecticut General
Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any
[Any] material, compound, mixture or preparation which contains their salts, isomers and salts of
isomers, [unless specifically excepted,] whenever the existence of these salts, isomers, and salts of
isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine;
(2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;
(3) 2,5-dimethoxyamphetamine; or 2,5-DMA;
(4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;
(5) 3,4-M ethylenedioxy-N-ethylamphetamine;
(6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;
(7) 3,4-methylenedioxymethamphetamine; or MDMA;
(8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);
(9) 4-methoxyamphetamine; or PMA;
(10) 5-methoxy-3,4-methylenedioxy-amphetamine;
(11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt);
(12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP;

(13) 3,4-methylenedioxy amphetamine; or MDA;
(14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha- methyl3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
(15) 3,4,5-trimethoxy amphetamine;
(16) benzylpiperazine or BZP;
(17) Bufotenine or Mappine;
(18) Alphaethyltryptamine;
(19) Diethyltryptamine or DET;
(20) Dimethyltryptamine or DMT;
(21) Ibogaine;
(22) Lysergic acid diethylamide;
(23) MDVP (3,4-methylenedioxypyrovalerone);
(24) 3,4-methylenedioxy-N-methycathione (methylone);
(25) Mephedrone (4-methylmethcathinone);
(26) Mescaline;
(27) Parahexyl or Synhexyl;
(28) Peyote, meaning all parts of the plants;
(29) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;
(30) N-ethyl-3-piperidyl benzilate;
(31) N-methyl-3-piperidyl benzilate;
(32) Psilocybin;
(33) Psilocyn;
(34) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a
soft gelatin capsule in a United States food and drug administration approved product;
(35) Salvia divinorum;
(36) Salvinorin A;
(37) Ethylamine analog of phencyclidine, Cyclohexamine or PCE;
(38) 4-Bromo-2,5-dimethoxyphenethylamine;
(39) Pyrrolidine analog of phencyclidine, PCP or PHP;
(40) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
(41) Thiophene analog of phencyclidine, TPCP or TCP;
(42) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;
(43) Trifluoromethylphenylpiperazine or TFMPP; [.]
(44) 7-hydroxymitragynine;
(45) Bromazolam;
(46) Flubromazolam;
(47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts;
(48) Nitazenes, including, but not limited to, isotonitazene;
(49) Tianeptine; and

(50) Phenibut.

Instrument

Schedule I hallucinogenic substances: 7-hydroxymitragynine; Mitragyna speciosa (kratom), including its leaves, stem and any extracts

Source

https://eregulations.ct.gov/eRegsPortal/Search/getDocument?guid=003D4E9D-0000-C41E-9994-EE4C018247EA

Retrieved

2026-10-29

Fingerprint

d49c5ca59c7d078f

(c) Unless specifically excepted or unless listed in another schedule in the Connecticut General
Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any
[Any] material, compound, mixture or preparation which contains their salts, isomers and salts of
isomers, [unless specifically excepted,] whenever the existence of these salts, isomers, and salts of
isomers is possible within the specific chemical designation:

(1) Alpha-ethyltryptamine;
(2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;
(3) 2,5-dimethoxyamphetamine; or 2,5-DMA;
(4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;
(5) 3,4-M ethylenedioxy-N-ethylamphetamine;
(6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;
(7) 3,4-methylenedioxymethamphetamine; or MDMA;
(8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);
(9) 4-methoxyamphetamine; or PMA;
(10) 5-methoxy-3,4-methylenedioxy-amphetamine;
(11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt);
(12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP;

Regulation - Page 3 of 7

Connecticut eRegulations System — Tracking Number PR2025-018 — Posted 4/2/2026

(13) 3,4-methylenedioxy amphetamine; or MDA;
(14)  N-hydroxy-3,4-methylenedioxyamphetamine  (also  known  as  N-hydroxy-alpha-  methyl-

3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;

(15) 3,4,5-trimethoxy amphetamine;
(16) benzylpiperazine or BZP;
(17) Bufotenine or Mappine;
(18) Alphaethyltryptamine;
(19) Diethyltryptamine or DET;
(20) Dimethyltryptamine or DMT;
(21) Ibogaine;
(22) Lysergic acid diethylamide;
(23) MDVP (3,4-methylenedioxypyrovalerone);
(24) 3,4-methylenedioxy-N-methycathione (methylone);
(25) Mephedrone (4-methylmethcathinone);
(26) Mescaline;
(27) Parahexyl or Synhexyl;
(28) Peyote, meaning all parts of the plants;
(29) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;
(30) N-ethyl-3-piperidyl benzilate;
(31) N-methyl-3-piperidyl benzilate;
(32) Psilocybin;
(33) Psilocyn;
(34) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a

soft gelatin capsule in a United States food and drug administration approved product;

(35) Salvia divinorum;
(36) Salvinorin A;
(37) Ethylamine analog of phencyclidine, Cyclohexamine or PCE;
(38) 4-Bromo-2,5-dimethoxyphenethylamine;
(39) Pyrrolidine analog of phencyclidine, PCP or PHP;
(40) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
(41) Thiophene analog of phencyclidine, TPCP or TCP;
(42) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;
(43) Trifluoromethylphenylpiperazine or TFMPP; [.]
(44) 7-hydroxymitragynine;
(45) Bromazolam;
(46) Flubromazolam;
(47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts;